SECRETED PROTEIN DEVELOPMENT AND COLLABORATION AGREEMENTDevelopment and Collaboration Agreement • March 29th, 2002 • Deltagen Inc • Services-commercial physical & biological research • California
Contract Type FiledMarch 29th, 2002 Company Industry Jurisdiction
RESEARCH SUBSCRIPTION AGREEMENTResearch Subscription Agreement • March 29th, 2002 • Deltagen Inc • Services-commercial physical & biological research
Contract Type FiledMarch 29th, 2002 Company IndustryTHIS RESEARCH SUBSCRIPTION AGREEMENT (the “Agreement”), effective as of February 8, 2002 (the “Effective Date”), is entered into between DELTAGEN, INC., a Delaware corporation with a place of business at 740 Bay Road, Redwood City, CA 94063, U.S.A. (“Deltagen”), and MERCK & CO., INC., a New Jersey corporation with a place of business at One Merck Drive, P.O. Box 100, Whitehouse Station, New Jersey 08889-0100 (“Merck”). Deltagen and Merck are sometimes referred to herein individually, as a “Party” and collectively, as the “Parties.”
LOAN AGREEMENTLoan Agreement • March 29th, 2002 • Deltagen Inc • Services-commercial physical & biological research
Contract Type FiledMarch 29th, 2002 Company Industry• The company DELTAGEN EUROPE S.A., a joint-stock company with a capital of 2,440,000.-Euros, with head-office at 44, Route Burkel in 67400 ILLKIRCH, registered at the Register of Trade and Companies of Strasbourg under the number B 434 277 919, represented by Mr William MATTHEWS, Ph. D., President of the Board of Directors
EMPLOYMENT AGREEMENTEmployment Agreement • March 29th, 2002 • Deltagen Inc • Services-commercial physical & biological research • California
Contract Type FiledMarch 29th, 2002 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (this “Agreement”) is made by and between Bristol-Myers Squibb Pharma Research Labs L.L.C., a Delaware limited liability company (hereinafter the “Company”), and Peter L. Myers (hereinafter “Employee”) and shall become effective upon the date of the latest signature hereto.
LEASE PURCHASE AGREEMENTPledge Agreement • March 29th, 2002 • Deltagen Inc • Services-commercial physical & biological research
Contract Type FiledMarch 29th, 2002 Company Industry• The company Alsacienne de Crédit-Bail Immobilier—ALSABAIL, mixed local economy company with a capital of € 9,704,280.—, head-office located at 5, Allée de la Robertsau in 67000 STRASBOURG, registered at the Register of Trade and Companies of STRASBOURG under the number B 718 504 004, represented by Mr René SUTTER, Director of Administration and Finance, duly empowered in this respect
STOCK PURCHASE AGREEMENTStock Purchase Agreement • March 29th, 2002 • Deltagen Inc • Services-commercial physical & biological research • California
Contract Type FiledMarch 29th, 2002 Company Industry JurisdictionThe undersigned, George Rathmann as an individual and/or as trustee for one or more trusts designated by him (collectively, the “Investor”), hereby confirms his agreement with you as follows:
LEASELease • March 29th, 2002 • Deltagen Inc • Services-commercial physical & biological research • California
Contract Type FiledMarch 29th, 2002 Company Industry JurisdictionTHIS LEASE (the “Lease”) is made as of February 23, 1999 between LMC-SHOREHAM INVESTMENT COMPANY, LLC, a California limited liability company, and CONVOY COURT INVESTMENT COMPANY, LLC, a California limited liability company, as tenants in common (the “Landlord”), and the Tenant named in the Schedule below.
CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. AGREEMENT AND PLAN OF MERGER AND REORGANIZATION dated as of...Agreement and Plan of Merger and Reorganization • March 29th, 2002 • Deltagen Inc • Services-commercial physical & biological research • California
Contract Type FiledMarch 29th, 2002 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION dated as of January 15, 2002 (this “Agreement”), is entered into by and among Deltagen, Inc., a Delaware corporation (“Acquiror”), XP Acquisition Corporation, a Delaware corporation and a wholly-owned subsidiary of Acquiror (“Sub”), and XenoPharm, Inc., a Delaware corporation (“Target”).